Profile: Paratek Pharmaceuticals Inc (PRTK.OQ)
14 Aug 2018
Paratek Pharmaceuticals, Inc. (Paratek), incorporated on February 27, 2001, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. It has generated small molecule therapeutic candidates based upon medicinal chemistry-based modifications, according to structure-based activity, of all positions of the core tetracycline molecule. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, and an oral, narrow-spectrum, tetracycline-derived compound with activity against Clostridium difficile in vitro and in a rodent model of Clostridium difficile-associated diarrhea.
The Company's antibacterial product candidate, omadacycline, is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI), where antibiotic resistance is of concern for treating physicians. In addition to its various antibacterial activity and its availability in once-daily oral and IV formulations, omadacycline appears to penetrate tissues broadly, including the lungs, muscle and kidneys, thereby achieving high concentrations at the sites of infection. Since omadacycline is eliminated from the body (as unchanged parent compound) via the kidneys and intestine in a balanced manner, the Company may use it in patients with diminished kidney and liver function, without dose adjustment. The Company has completed clinical Phase I studies with omadacycline that are needed for inclusion in the planned New Drug Application (NDA).
The Company's Phase III antibacterial product candidate is sarecycline, also known as WC3035. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Paratek Pharmaceuticals Inc
75 Park Plz Ste 4
BOSTON MA 02116-3934
Company Web Links
- UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic
- U.S. FDA panel backs approval of Paratek's antibiotic
- UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff
- Paratek antibiotic not inferior to current treatments-FDA staff
- BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91